A single-dose live attenuated chimeric vaccine candidate against Zika virus

The mosquito-borne Zika virus is an emerging pathogen from the Flavivirus genus for which there are no approved antivirals or vaccines. Using the clinically validated PDK-53 dengue virus vaccine strain as a backbone, we created a chimeric dengue/Zika virus, VacDZ, as a live attenuated vaccine candid...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, Wei-Xin, Lee, Regina Ching Hua, Kaur, Parveen, Lew, Tian Sheng, Yogarajah, Thinesshwary, Kong, Hao Yuin, Teo, Zi-Yun, Salim, Cyrill Kafi, Zhang, Rong-Rong, Li, Xiao-Feng, Alonso, Sylvie, Qin, Cheng-Feng, Chu, Justin Jang Hann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846741/
https://www.ncbi.nlm.nih.gov/pubmed/33514743
http://dx.doi.org/10.1038/s41541-021-00282-y
Descripción
Sumario:The mosquito-borne Zika virus is an emerging pathogen from the Flavivirus genus for which there are no approved antivirals or vaccines. Using the clinically validated PDK-53 dengue virus vaccine strain as a backbone, we created a chimeric dengue/Zika virus, VacDZ, as a live attenuated vaccine candidate against Zika virus. VacDZ demonstrates key markers of attenuation: small plaque phenotype, temperature sensitivity, attenuation of neurovirulence in suckling mice, and attenuation of pathogenicity in interferon deficient adult AG129 mice. VacDZ may be administered as a traditional live virus vaccine, or as a DNA-launched vaccine that produces live VacDZ in vivo after delivery. Both vaccine formulations induce a protective immune response against Zika virus in AG129 mice, which includes neutralising antibodies and a strong Th1 response. This study demonstrates that VacDZ is a safe and effective vaccine candidate against Zika virus.

Ejemplares similares